Panelists discuss how overcoming logistical and perceptual barriers will drive wider adoption of SC therapies in NSCLC.

“The monoclonal antibodies rituximab, ocrelizumab, ofatumumab (Kesimpta), and ublituximab (Briumvi) provide outstanding ...

Hearn Jay Cho, MD, PhD, chief medical officer at the Multiple Myeloma Research Foundation, shared insights on what end points ...

Patients with chronic spontaneous urticaria (CSU) experienced improved quality of life and sleep when symptoms were mitigated ...

Patients with rheumatoid arthritis (RA) have a higher risk of osteoporotic fractures if they have elevated adipokines, according to a recent report. 1 However, the investigators behind the study, ...

Combining genetic features with clinical data improved the performance of a pulmonary fibrosis prediction score for people with rheumatoid arthritis. A new combined risk score that incorporates ...

Zachary Contreras from Sharp Health Plan discusses findings from the AMCP Nexus study showing that dextromethorphan-bupropion ...

Sibeprenlimab gains accelerated approval from the FDA for IgA nephropathy, showing significant proteinuria reduction and ...

Patients with age-related macular degeneration (AMD) or polypoidal choroidal vasculopathy (PCV) who had not been treated previously were found to have better control of pigment epithelial detachment ...

Zachary Contreras from Sharp Health Plan explains how managed care organizations can support early adoption of DM-BUP to ...

Eleanor Perfetto, PhD, explores how most favored nation policy relates to broader drug pricing and cost-effectiveness debates ...

In the KEYNOTE-B96 trial ( NCT05116189 ), weekly paclitaxel with bevacizumab and pembrolizumab (Keytruda; Merck) demonstrated ...